期刊
CCS CHEMISTRY
卷 1, 期 2, 页码 226-236出版社
CHINESE CHEMICAL SOC
DOI: 10.31635/ccschem.019.20180038
关键词
antibody-drug conjugates; bioorthogonal prodrug; iEDDA reaction; enhanced tumor penetration; alleviated side effects
Current antibody-drug conjugates (ADCs) suffer from low tissue penetration and significant side effects, largely due to the permanent linkage and/or premature release of cytotoxic payloads. Herein, we developed a prodrug-antibody conjugate (ProADC) strategy by conjugating a bioorthogonal-activatable prodrug with an antibody that allowed on-target release and on-demand activation of cytotoxic drugs at a tumor site. The bioorthogonal-caged prodrug exhibited an enhanced permeability into and on-demand activation within cancer cells, while the pH-sensitive ADC linker allowed on-target release of the anticancer agent. Together, the ProADCs showed enhanced tumor penetration and alleviated side effects for use as an on-target and on-demand chemotherapy agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据